



20 August 2026

Strong 1Q27 supports growth outlook

BLIS Technologies Limited (BLIS) delivered revenue of \$5.1m, for the first quarter ended 30 June 2026 (1Q27), an increase of \$1.5m, or up 42%, on the same period last year. 1Q27 EBITDA was a \$1.1m profit compared to a \$0.2m loss for 1Q26. The 1Q27 financial information is unaudited and in New Zealand dollars.

B2B revenue was up 67% on 1Q26 driven by ingredient growth in Asia Pacific, strong Probi royalties and private label sales into China, partially offset by weaker ingredient revenue in Europe. Total B2C revenue was up 4% on 1Q26.

“We have had an exceptional start to the year, with record revenue and EBITDA. Although the first quarter should not be annualised to a full year, we are comfortable with our current forecast of 10%-15% revenue growth for FY27.” said Scott Johnson, CEO.

Ends

For further information, please contact:

Scott Johnson
CEO
+64 21 488 831

About BLIS Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics

BLIS Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Asia, Europe and the USA. More information about BLIS Technologies Ltd can be found at www.blis.co.nz.

Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics